PF-562271 HCl: Unlocking Advanced FAK/Pyk2 Inhibition in Cancer Research

Principle and Setup: The Science Behind PF-562271 HCl

PF-562271 HCl is a next-generation ATP-competitive FAK inhibitor that has rapidly become a cornerstone in cancer research and drug discovery. As the hydrochloride salt form of PF-562271, this compound offers potent, reversible inhibition of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2)—two kinases central to cellular adhesion, migration, and survival. With an impressive IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, PF-562271 HCl demonstrates approximately tenfold selectivity for FAK over Pyk2 and >100-fold selectivity over most other kinases, except some cyclin-dependent kinases (CDKs).

FAK and Pyk2 are non-receptor tyrosine kinases implicated in cancer cell motility, invasion, and the complex interplay of tumor microenvironment modulation. By inhibiting FAK phosphorylation (EC₅₀: 93 ng/mL in tumor-bearing mouse models), PF-562271 HCl delivers robust tumor growth inhibition and offers a compelling platform for both mechanistic and translational oncology studies (Moret et al., 2019).

For those seeking a high-performance tool to interrogate FAK/Pyk2 signaling pathways, this inhibitor’s profile aligns with the best-practice recommendations for selectivity and off-target minimization established by modern cheminformatics approaches (Moret et al., 2019).

Step-by-Step Workflow: Protocol Enhancements with PF-562271 HCl

Compound Handling and Storage

• Solubility: PF-562271 HCl is readily soluble at ≥26.35 mg/mL in DMSO when gently warmed. It is insoluble in water and ethanol, so all experimental solutions should be prepared freshly in DMSO.
• Storage: The compound is supplied as a solid and should be stored at -20°C. For optimal stability, avoid long-term storage of solutions; use freshly prepared stocks within the same day.

Experimental Workflow

1. Preparation of Stock Solution: Dissolve PF-562271 HCl in DMSO to the desired concentration (e.g., 10 mM). Warm gently to expedite dissolution if necessary.
2. Working Dilutions: Dilute the DMSO stock into cell culture medium or assay buffer immediately before use. The final DMSO concentration should not exceed 0.1–0.2% to prevent cytotoxicity.
3. Cell-based Assays: Add the inhibitor to cell lines or primary cells to interrogate FAK/Pyk2-driven signaling, migration, or survival. Time-course and dose-response studies are recommended to capture both acute and chronic effects.
4. In Vivo Studies: For animal models, PF-562271 HCl can be administered according to published dosing regimens that achieve plasma concentrations sufficient for FAK phosphorylation inhibition (target EC₅₀: 93 ng/mL).
5. Readouts: Assess FAK phosphorylation (e.g., p-FAK Tyr397 by Western blot or ELISA), cell migration (scratch-wound, transwell), or tumor volume progression in vivo. Incorporate controls using selective inhibitors to validate specificity.

For a comprehensive, stepwise protocol and product data, refer to the PF-562271 HCl product page.

Advanced Applications and Comparative Advantages

The strategic application of PF-562271 HCl enables researchers to dissect both canonical and emerging roles of FAK/Pyk2 in cancer biology. Notably, its high selectivity profile makes it ideal for:

• Dissecting FAK/Pyk2 Signaling: Its low nanomolar potency allows for precise modulation of the focal adhesion kinase signaling pathway without off-target interference, as shown in the design principles outlined by Moret et al. (2019).
• Tumor Microenvironment Modulation: PF-562271 HCl has been leveraged to unravel the crosstalk between cancer cells, stromal fibroblasts, and immune infiltration, offering a platform for studying tumor progression in a physiologically relevant context (Malotilate.com).
• Combination Therapy Development: Its reversible inhibition supports combination screens with cytotoxic agents or immunomodulators, facilitating the identification of synergistic mechanisms or resistance pathways.
• Library Optimization: As highlighted in cheminformatics analyses, highly selective kinase inhibitors like PF-562271 HCl are integral to the design of focused libraries with minimal off-target overlap, maximizing data quality in both high-throughput and phenotypic screening campaigns.

For translational oncology strategies that integrate biomarker-driven and immunomodulatory approaches, PF-562271 HCl complements the paradigm shift described in Advancing Translational Oncology, and extends the mechanistic insight provided in Redefining Cancer Research.

Troubleshooting and Optimization Tips

• Solubility Issues: If precipitation is observed upon dilution, ensure the DMSO stock is fully dissolved and that the addition to aqueous media is gradual with thorough mixing. Avoid exceeding recommended final DMSO concentrations.
• Compound Stability: Prepare working solutions immediately before use. If extended storage is unavoidable, aliquot and store at -80°C to minimize freeze-thaw cycles.
• Non-specific Effects: Include vehicle (DMSO) controls and, where possible, use orthogonal FAK/Pyk2 inhibitors to confirm on-target activity. Monitor for off-target CDK effects at higher concentrations.
• Assay Sensitivity: Use sensitive and quantitative readouts (e.g., phospho-FAK ELISA) to detect subtle changes in kinase activity, especially when screening for partial inhibition or in primary cell models.
• In Vivo Dosing: Reference established pharmacokinetic and pharmacodynamic data to avoid subtherapeutic or toxic exposures; target plasma levels corresponding to the EC₅₀ for FAK phosphorylation inhibition (93 ng/mL).

For detailed troubleshooting strategies and comparative guidance, see PF-562271 HCl: A Next-Generation FAK/Pyk2 Inhibitor for Tumor Microenvironment Research, which complements this workflow by providing real-world case studies and performance benchmarks.

Future Outlook: Integrating PF-562271 HCl into Precision Oncology

The future of FAK/Pyk2 inhibition in cancer research lies at the intersection of targeted therapy, systems biology, and immuno-oncology. As data-driven library design continues to evolve, as illustrated by Moret et al. (2019), compounds like PF-562271 HCl will play a pivotal role in expanding the diversity and selectivity of small-molecule toolkits. Its robust performance and well-characterized selectivity profile position it as a model for next-generation kinase inhibitors—enabling not only pathway dissection but also the rational design of multi-agent therapeutic regimens.

By integrating PF-562271 HCl into phenotypic and high-content screens, researchers can accelerate the translation of bench discoveries into clinical insights, particularly in the context of tumor microenvironment modulation, metastatic progression, and resistance mechanisms. The continued refinement of cheminformatics tools and mechanism-of-action libraries will further optimize the utility of selective inhibitors, paving the way for precision oncology and beyond.

For comprehensive product information, protocols, and ordering details, visit the official PF-562271 HCl resource page.